DWA
NBSE

Dorsey Wright & Associates’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Dorsey Wright & Associates’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-79
Closed -$14K – 379
2020
Q2 		$14K Hold
79
– – ﹤0.01% 190
2020
Q1 		$11K Buy
+79
New +$10.5K ﹤0.01% 134

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Dorsey Wright & Associates's NBSE Position: Q3 2020 in Review

Dorsey Wright & Associates sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2020, closing a stake of 79 shares — an estimated $14K sold.

Dorsey Wright & Associates first reported a position in NBSE in Q1 2020 and held it in 2 quarters. The position peaked at $14K in Q2 2020. 50 funds tracked by Wall St. Rank hold NBSE as of Q3 2020.

  • Dorsey Wright & Associates reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 79 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $14K.
  • Dorsey Wright & Associates first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2020 and held it in 2 quarters.
  • Dorsey Wright & Associates's NeuBase Therapeutics, Inc. Common Stock position peaked at $14K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Dorsey Wright & Associates's 13F filing for Q3 2020, filed 28 Oct 2020.